^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CDK19 inhibitor

    7ms
    ROVER-01: RVU120 Rollover Study (clinicaltrials.gov)
    P2, N=10, Not yet recruiting, Ryvu Therapeutics SA
    New P2 trial
    |
    romaciclib (RVU120)
    8ms
    RIVER-52: Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML (clinicaltrials.gov)
    P2, N=94, Active, not recruiting, Ryvu Therapeutics SA | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    romaciclib (RVU120)
    10ms
    CDK8/19 inhibition attenuates G1 arrest induced by BCR-ABL antagonists and accelerates death of chronic myelogenous leukemia cells. (PubMed, Cell Death Discov)
    Imatinib mesylate (IM) and other BCR-ABL tyrosine kinase inhibitors (BCR-ABLi) are the mainstay of chronic myelogenous leukemia (CML) treatment...Dissecting the effects of pharmacological CDK8/19 inhibition on CML survival in response to BCR-ABLi, we found that a selective, non-toxic CDK8/19 inhibitor (CDK8/19i) Senexin B (SenB) and other CDK8/19i sensitized K562 cells to different BCR-ABLi via attenuation of cell cycle arrest...In contrast, IM-treated BCR-ABL-positive KU812 CML cells, which did not induce p27Kip1, readily died regardless of SenB treatment. Thus, CDK8/19i prevent the quiescence-mediated escape from BCR-ABLi-induced apoptosis, suggesting a strategy for avoiding the CML relapse.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CASP9 (Caspase 9) • ANXA5 (Annexin A5)
    |
    imatinib • Senexin B
    11ms
    Zinc finger protein 169 promotes tumor progress of hepatocellular cancer via up-regulating cyclin-dependent kinase 19. (PubMed, IUBMB Life)
    Furthermore, recovery experiments demonstrated that CDK19 could reverse the impact of ZNF169 on HCC cell amplification. Our findings indicate that ZNF169 promotes HCC progression by upregulating CDK19, highlighting its role as a therapeutic target or prognostic biomarker for HCC.
    Journal
    |
    CDK9 (Cyclin Dependent Kinase 9)
    1year
    RVU120-SOL-021: RVU120 (SEL120) in Patients with Relapse/Refractory Metastatic or Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=120, Active, not recruiting, Ryvu Therapeutics SA | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER expression
    |
    romaciclib (RVU120)
    1year
    POTAMI-61: RVU120 in Patients with Intermediate or High-risk, Primary or Secondary Myelofibrosis (clinicaltrials.gov)
    P2, N=230, Recruiting, Ryvu Therapeutics SA | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Jakafi (ruxolitinib) • romaciclib (RVU120)
    over1year
    POTAMI-61: RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis (clinicaltrials.gov)
    P2, N=230, Not yet recruiting, Ryvu Therapeutics SA
    New P2 trial • Combination therapy
    |
    Jakafi (ruxolitinib) • romaciclib (RVU120)
    over1year
    Novel CDK19-Targeted Radiotracers: A Potential Design Strategy to Improve the Pharmacokinetics and Tumor Uptake. (PubMed, J Med Chem)
    The ligand 68Ga-10c demonstrated high absorption in tumor 5 min after injection and sustains long-term imaging within 3 h. Furthermore, 68Ga-10c exhibited slow clearance within the tumor and was predominantly metabolized in both the liver and kidneys, showing the potential to alleviate metabolic pressure and enhance tissue safety. Therefore, the linker optimization strategy is well suited for CDK19 and provides a reference for the radioactive ligands of other nuclear targets.
    PK/PD data • Journal
    |
    CDK9 (Cyclin Dependent Kinase 9)
    almost2years
    RIVER-52: Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML (clinicaltrials.gov)
    P2, N=94, Recruiting, Ryvu Therapeutics SA
    New P2 trial
    |
    romaciclib (RVU120)
    almost2years
    REMARK_001: RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms (clinicaltrials.gov)
    P2, N=41, Not yet recruiting, GCP-Service International West GmbH
    New P2 trial
    |
    romaciclib (RVU120)
    almost2years
    CD24 induced cellular quiescence-like state and chemoresistance in ovarian cancer cells via miR-130a/301a-dependent CDK19 downregulation. (PubMed, Cell Death Discov)
    Our results showed that CD24 expression may induce a cellular quiescence-like state and resistance to platinum-based chemotherapeutic agents in ovarian cancer via miR-130a and 301a upregulation. CD24-miR-130a/301a-CDK19 signaling axis could be a prognostic marker for or a potential therapeutic target against ovarian cancer recurrence.
    Journal
    |
    CD24 (CD24 Molecule) • CDK9 (Cyclin Dependent Kinase 9) • MIR199A1 (MicroRNA 199a-1) • MIR199A (MicroRNA 199a) • MIR130A (MicroRNA 130a) • STAT4 (Signal Transducer And Activator Of Transcription 4) • YY1 (YY1 Transcription Factor)
    |
    CD24 overexpression • CD2 overexpression • CD24 expression
    almost2years
    CLI120-001: RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome (clinicaltrials.gov)
    P1, N=112, Active, not recruiting, Ryvu Therapeutics SA | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    romaciclib (RVU120)